Clonazepam treatment of five lithium-refractory patients with bipolar disorder.
The authors describe the first five patients enrolled in an open clinical trial of clonazepam as a maintenance treatment in lithium-refractory bipolar disorder. All patients relapsed quickly after taking clonazepam (one within 2 weeks and four within 10-15 weeks), and the study was prematurely terminated. The results cast doubt over the usefulness of clonazepam as a prophylaxis in lithium-resistant bipolar patients who have histories of psychotic mania or delusional depression.
Aronson
T A
TA
Department of Psychiatry and Behavioral Science, State University of New York, Stony Brook 11794-8101.
Shukla
S
S
Hirschowitz
J
J
D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D002998:Clonazepam / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012008:Recurrence
D002998:Clonazepam; D008094:Lithium